nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Tazarotene—psoriasis	0.121	0.232	CbGbCtD
Trametinib—CYP2C8—Cholecalciferol—psoriasis	0.0519	0.0989	CbGbCtD
Trametinib—CYP2C8—Mycophenolate mofetil—psoriasis	0.045	0.0858	CbGbCtD
Trametinib—CYP3A4—Calcitriol—psoriasis	0.0408	0.0779	CbGbCtD
Trametinib—CYP2C8—Hydrocortisone—psoriasis	0.0361	0.0688	CbGbCtD
Trametinib—CYP2C8—Cyclosporine—psoriasis	0.0341	0.065	CbGbCtD
Trametinib—CYP3A4—Methoxsalen—psoriasis	0.0318	0.0606	CbGbCtD
Trametinib—CYP2C8—Dexamethasone—psoriasis	0.0224	0.0428	CbGbCtD
Trametinib—CYP3A4—Cholecalciferol—psoriasis	0.021	0.0401	CbGbCtD
Trametinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.0182	0.0348	CbGbCtD
Trametinib—CYP3A4—Triamcinolone—psoriasis	0.0182	0.0348	CbGbCtD
Trametinib—CYP3A4—Betamethasone—psoriasis	0.0156	0.0298	CbGbCtD
Trametinib—CYP3A4—Prednisolone—psoriasis	0.0154	0.0294	CbGbCtD
Trametinib—CYP3A4—Hydrocortisone—psoriasis	0.0146	0.0279	CbGbCtD
Trametinib—CYP3A4—Prednisone—psoriasis	0.0146	0.0278	CbGbCtD
Trametinib—CYP3A4—Cyclosporine—psoriasis	0.0138	0.0264	CbGbCtD
Trametinib—CYP3A4—Dexamethasone—psoriasis	0.0091	0.0174	CbGbCtD
Trametinib—Infection—Mycophenolate mofetil—psoriasis	0.000144	0.00051	CcSEcCtD
Trametinib—Hyperhidrosis—Cyclosporine—psoriasis	0.000143	0.000509	CcSEcCtD
Trametinib—Hypertension—Prednisolone—psoriasis	0.000143	0.000507	CcSEcCtD
Trametinib—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000142	0.000504	CcSEcCtD
Trametinib—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000141	0.000503	CcSEcCtD
Trametinib—Arrhythmia—Dexamethasone—psoriasis	0.000141	0.000503	CcSEcCtD
Trametinib—Arrhythmia—Betamethasone—psoriasis	0.000141	0.000503	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—psoriasis	0.000141	0.000502	CcSEcCtD
Trametinib—Skin disorder—Mycophenolate mofetil—psoriasis	0.00014	0.000499	CcSEcCtD
Trametinib—Bradycardia—Prednisone—psoriasis	0.00014	0.000499	CcSEcCtD
Trametinib—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00014	0.000496	CcSEcCtD
Trametinib—Hypertension—Hydrocortisone—psoriasis	0.000139	0.000495	CcSEcCtD
Trametinib—Vomiting—Hydroxyurea—psoriasis	0.000139	0.000494	CcSEcCtD
Trametinib—Haemoglobin—Prednisone—psoriasis	0.000139	0.000492	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—psoriasis	0.000138	0.00049	CcSEcCtD
Trametinib—Haemorrhage—Prednisone—psoriasis	0.000138	0.00049	CcSEcCtD
Trametinib—Rash—Hydroxyurea—psoriasis	0.000138	0.00049	CcSEcCtD
Trametinib—Erythema—Dexamethasone—psoriasis	0.000138	0.00049	CcSEcCtD
Trametinib—Erythema—Betamethasone—psoriasis	0.000138	0.00049	CcSEcCtD
Trametinib—Dermatitis—Hydroxyurea—psoriasis	0.000138	0.000489	CcSEcCtD
Trametinib—Myalgia—Hydrocortisone—psoriasis	0.000137	0.000488	CcSEcCtD
Trametinib—Headache—Hydroxyurea—psoriasis	0.000137	0.000487	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000136	0.000485	CcSEcCtD
Trametinib—Connective tissue disorder—Prednisone—psoriasis	0.000135	0.000481	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000135	0.00048	CcSEcCtD
Trametinib—Oedema—Prednisolone—psoriasis	0.000135	0.000479	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—psoriasis	0.000135	0.000478	CcSEcCtD
Trametinib—Insomnia—Cyclosporine—psoriasis	0.000134	0.000476	CcSEcCtD
Trametinib—Cough—Triamcinolone—psoriasis	0.000133	0.000471	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000132	0.000468	CcSEcCtD
Trametinib—Oedema—Hydrocortisone—psoriasis	0.000132	0.000468	CcSEcCtD
Trametinib—Asthenia—Mycophenolic acid—psoriasis	0.000131	0.000467	CcSEcCtD
Trametinib—Hypertension—Triamcinolone—psoriasis	0.000131	0.000466	CcSEcCtD
Trametinib—Infection—Hydrocortisone—psoriasis	0.000131	0.000465	CcSEcCtD
Trametinib—Insomnia—Mycophenolate mofetil—psoriasis	0.000131	0.000464	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisolone—psoriasis	0.00013	0.000463	CcSEcCtD
Trametinib—Nausea—Hydroxyurea—psoriasis	0.00013	0.000461	CcSEcCtD
Trametinib—Pruritus—Mycophenolic acid—psoriasis	0.00013	0.00046	CcSEcCtD
Trametinib—Myalgia—Triamcinolone—psoriasis	0.000129	0.000459	CcSEcCtD
Trametinib—Nervous system disorder—Hydrocortisone—psoriasis	0.000129	0.000459	CcSEcCtD
Trametinib—Eye disorder—Prednisone—psoriasis	0.000129	0.000458	CcSEcCtD
Trametinib—Decreased appetite—Cyclosporine—psoriasis	0.000129	0.000458	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—psoriasis	0.000128	0.000456	CcSEcCtD
Trametinib—Infestation—Methotrexate—psoriasis	0.000128	0.000456	CcSEcCtD
Trametinib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000128	0.000454	CcSEcCtD
Trametinib—Skin disorder—Hydrocortisone—psoriasis	0.000128	0.000454	CcSEcCtD
Trametinib—Fatigue—Cyclosporine—psoriasis	0.000128	0.000454	CcSEcCtD
Trametinib—Hyperhidrosis—Hydrocortisone—psoriasis	0.000127	0.000452	CcSEcCtD
Trametinib—Constipation—Cyclosporine—psoriasis	0.000127	0.00045	CcSEcCtD
Trametinib—Dry mouth—Triamcinolone—psoriasis	0.000126	0.000449	CcSEcCtD
Trametinib—Renal failure—Methotrexate—psoriasis	0.000126	0.000448	CcSEcCtD
Trametinib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000126	0.000446	CcSEcCtD
Trametinib—Diarrhoea—Mycophenolic acid—psoriasis	0.000125	0.000445	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—psoriasis	0.000125	0.000445	CcSEcCtD
Trametinib—Angiopathy—Prednisone—psoriasis	0.000125	0.000444	CcSEcCtD
Trametinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000125	0.000443	CcSEcCtD
Trametinib—Oedema—Triamcinolone—psoriasis	0.000124	0.00044	CcSEcCtD
Trametinib—Constipation—Mycophenolate mofetil—psoriasis	0.000124	0.000439	CcSEcCtD
Trametinib—Arrhythmia—Prednisone—psoriasis	0.000123	0.000438	CcSEcCtD
Trametinib—Infection—Triamcinolone—psoriasis	0.000123	0.000438	CcSEcCtD
Trametinib—Haematuria—Methotrexate—psoriasis	0.000122	0.000435	CcSEcCtD
Trametinib—Insomnia—Prednisolone—psoriasis	0.000122	0.000433	CcSEcCtD
Trametinib—Gastrointestinal pain—Cyclosporine—psoriasis	0.000121	0.00043	CcSEcCtD
Trametinib—Dizziness—Mycophenolic acid—psoriasis	0.000121	0.00043	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—psoriasis	0.000121	0.00043	CcSEcCtD
Trametinib—Mental disorder—Prednisone—psoriasis	0.000121	0.000429	CcSEcCtD
Trametinib—Malnutrition—Prednisone—psoriasis	0.00012	0.000426	CcSEcCtD
Trametinib—Erythema—Prednisone—psoriasis	0.00012	0.000426	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.00012	0.000426	CcSEcCtD
Trametinib—Hyperhidrosis—Triamcinolone—psoriasis	0.00012	0.000426	CcSEcCtD
Trametinib—Insomnia—Hydrocortisone—psoriasis	0.000119	0.000423	CcSEcCtD
Trametinib—Hypertension—Betamethasone—psoriasis	0.000119	0.000423	CcSEcCtD
Trametinib—Hypertension—Dexamethasone—psoriasis	0.000119	0.000423	CcSEcCtD
Trametinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000118	0.00042	CcSEcCtD
Trametinib—Myalgia—Betamethasone—psoriasis	0.000117	0.000417	CcSEcCtD
Trametinib—Myalgia—Dexamethasone—psoriasis	0.000117	0.000417	CcSEcCtD
Trametinib—Body temperature increased—Cyclosporine—psoriasis	0.000117	0.000416	CcSEcCtD
Trametinib—Abdominal pain—Cyclosporine—psoriasis	0.000117	0.000416	CcSEcCtD
Trametinib—Vomiting—Mycophenolic acid—psoriasis	0.000116	0.000414	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—psoriasis	0.000116	0.000412	CcSEcCtD
Trametinib—Rash—Mycophenolic acid—psoriasis	0.000115	0.00041	CcSEcCtD
Trametinib—Dermatitis—Mycophenolic acid—psoriasis	0.000115	0.00041	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—psoriasis	0.000115	0.000409	CcSEcCtD
Trametinib—Headache—Mycophenolic acid—psoriasis	0.000115	0.000408	CcSEcCtD
Trametinib—Decreased appetite—Hydrocortisone—psoriasis	0.000114	0.000407	CcSEcCtD
Trametinib—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000114	0.000406	CcSEcCtD
Trametinib—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000114	0.000406	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—psoriasis	0.000114	0.000404	CcSEcCtD
Trametinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000114	0.000404	CcSEcCtD
Trametinib—Fatigue—Hydrocortisone—psoriasis	0.000114	0.000403	CcSEcCtD
Trametinib—Vision blurred—Prednisone—psoriasis	0.000113	0.000402	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—psoriasis	0.000113	0.000401	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000113	0.000401	CcSEcCtD
Trametinib—Oedema—Dexamethasone—psoriasis	0.000112	0.0004	CcSEcCtD
Trametinib—Oedema—Betamethasone—psoriasis	0.000112	0.0004	CcSEcCtD
Trametinib—Insomnia—Triamcinolone—psoriasis	0.000112	0.000398	CcSEcCtD
Trametinib—Infection—Betamethasone—psoriasis	0.000112	0.000397	CcSEcCtD
Trametinib—Infection—Dexamethasone—psoriasis	0.000112	0.000397	CcSEcCtD
Trametinib—Anaemia—Prednisone—psoriasis	0.000111	0.000394	CcSEcCtD
Trametinib—Nervous system disorder—Dexamethasone—psoriasis	0.00011	0.000392	CcSEcCtD
Trametinib—Nervous system disorder—Betamethasone—psoriasis	0.00011	0.000392	CcSEcCtD
Trametinib—Thrombocytopenia—Dexamethasone—psoriasis	0.00011	0.000391	CcSEcCtD
Trametinib—Thrombocytopenia—Betamethasone—psoriasis	0.00011	0.000391	CcSEcCtD
Trametinib—Nausea—Mycophenolic acid—psoriasis	0.000109	0.000386	CcSEcCtD
Trametinib—Hyperhidrosis—Betamethasone—psoriasis	0.000109	0.000386	CcSEcCtD
Trametinib—Hyperhidrosis—Dexamethasone—psoriasis	0.000109	0.000386	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—psoriasis	0.000108	0.000383	CcSEcCtD
Trametinib—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000108	0.000383	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—psoriasis	0.000107	0.00038	CcSEcCtD
Trametinib—Fatigue—Triamcinolone—psoriasis	0.000107	0.00038	CcSEcCtD
Trametinib—Asthenia—Cyclosporine—psoriasis	0.000106	0.000378	CcSEcCtD
Trametinib—Pruritus—Cyclosporine—psoriasis	0.000105	0.000372	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—psoriasis	0.000105	0.000371	CcSEcCtD
Trametinib—Body temperature increased—Hydrocortisone—psoriasis	0.000104	0.00037	CcSEcCtD
Trametinib—Abdominal pain—Hydrocortisone—psoriasis	0.000104	0.00037	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—psoriasis	0.000104	0.000369	CcSEcCtD
Trametinib—Asthenia—Mycophenolate mofetil—psoriasis	0.000104	0.000368	CcSEcCtD
Trametinib—Hypertension—Prednisone—psoriasis	0.000104	0.000368	CcSEcCtD
Trametinib—Chills—Methotrexate—psoriasis	0.000103	0.000367	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000102	0.000364	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000102	0.000364	CcSEcCtD
Trametinib—Pruritus—Mycophenolate mofetil—psoriasis	0.000102	0.000363	CcSEcCtD
Trametinib—Myalgia—Prednisone—psoriasis	0.000102	0.000363	CcSEcCtD
Trametinib—Arthralgia—Prednisone—psoriasis	0.000102	0.000363	CcSEcCtD
Trametinib—Insomnia—Dexamethasone—psoriasis	0.000102	0.000361	CcSEcCtD
Trametinib—Insomnia—Betamethasone—psoriasis	0.000102	0.000361	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000101	0.000361	CcSEcCtD
Trametinib—Diarrhoea—Cyclosporine—psoriasis	0.000101	0.00036	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—psoriasis	0.000101	0.000359	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—psoriasis	0.0001	0.000356	CcSEcCtD
Trametinib—Erythema—Methotrexate—psoriasis	0.0001	0.000356	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—HLA-E—psoriasis	9.92e-05	0.00051	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—STAT3—psoriasis	9.92e-05	0.00051	CbGpPWpGaD
Trametinib—MAP2K1—IGF1R signaling cascade—IL6—psoriasis	9.91e-05	0.00051	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	9.91e-05	0.00051	CbGpPWpGaD
Trametinib—MAP2K1—Insulin receptor signalling cascade—IL6—psoriasis	9.91e-05	0.00051	CbGpPWpGaD
Trametinib—Diarrhoea—Mycophenolate mofetil—psoriasis	9.89e-05	0.000351	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—psoriasis	9.82e-05	0.000349	CcSEcCtD
Trametinib—MAP2K2—Focal Adhesion—JUN—psoriasis	9.81e-05	0.000505	CbGpPWpGaD
Trametinib—Body temperature increased—Triamcinolone—psoriasis	9.8e-05	0.000348	CcSEcCtD
Trametinib—Dizziness—Cyclosporine—psoriasis	9.8e-05	0.000348	CcSEcCtD
Trametinib—Oedema—Prednisone—psoriasis	9.8e-05	0.000348	CcSEcCtD
Trametinib—Decreased appetite—Dexamethasone—psoriasis	9.78e-05	0.000347	CcSEcCtD
Trametinib—Decreased appetite—Betamethasone—psoriasis	9.78e-05	0.000347	CcSEcCtD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—IL6—psoriasis	9.75e-05	0.000502	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—NFKB1—psoriasis	9.75e-05	0.000502	CbGpPWpGaD
Trametinib—MAP2K1—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	9.74e-05	0.000501	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TP53—psoriasis	9.74e-05	0.000501	CbGpPWpGaD
Trametinib—Infection—Prednisone—psoriasis	9.73e-05	0.000346	CcSEcCtD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	9.72e-05	0.0005	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Dexamethasone—psoriasis	9.71e-05	0.000345	CcSEcCtD
Trametinib—Gastrointestinal disorder—Betamethasone—psoriasis	9.71e-05	0.000345	CcSEcCtD
Trametinib—Back pain—Methotrexate—psoriasis	9.7e-05	0.000345	CcSEcCtD
Trametinib—Fatigue—Betamethasone—psoriasis	9.7e-05	0.000345	CcSEcCtD
Trametinib—Fatigue—Dexamethasone—psoriasis	9.7e-05	0.000345	CcSEcCtD
Trametinib—MAP2K2—Downstream signal transduction—STAT3—psoriasis	9.69e-05	0.000499	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—STAT3—psoriasis	9.64e-05	0.000496	CbGpPWpGaD
Trametinib—Nervous system disorder—Prednisone—psoriasis	9.61e-05	0.000341	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—CCL20—psoriasis	9.59e-05	0.000493	CbGpPWpGaD
Trametinib—Dizziness—Mycophenolate mofetil—psoriasis	9.56e-05	0.00034	CcSEcCtD
Trametinib—Skin disorder—Prednisone—psoriasis	9.51e-05	0.000338	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—psoriasis	9.47e-05	0.000336	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—TAGAP—psoriasis	9.45e-05	0.000486	CbGpPWpGaD
Trametinib—Vision blurred—Methotrexate—psoriasis	9.45e-05	0.000336	CcSEcCtD
Trametinib—Asthenia—Hydrocortisone—psoriasis	9.45e-05	0.000336	CcSEcCtD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	9.44e-05	0.000485	CbGpPWpGaD
Trametinib—Vomiting—Cyclosporine—psoriasis	9.42e-05	0.000335	CcSEcCtD
Trametinib—MAP2K2—VEGFA-VEGFR2 Pathway—IL6—psoriasis	9.39e-05	0.000483	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	9.35e-05	0.000481	CbGpPWpGaD
Trametinib—MAP2K1—MyD88-independent cascade—IL6—psoriasis	9.35e-05	0.000481	CbGpPWpGaD
Trametinib—Rash—Cyclosporine—psoriasis	9.34e-05	0.000332	CcSEcCtD
Trametinib—Dermatitis—Cyclosporine—psoriasis	9.33e-05	0.000332	CcSEcCtD
Trametinib—MAP2K2—Signaling by Interleukins—IL6—psoriasis	9.32e-05	0.000479	CbGpPWpGaD
Trametinib—Pruritus—Hydrocortisone—psoriasis	9.31e-05	0.000331	CcSEcCtD
Trametinib—Headache—Cyclosporine—psoriasis	9.28e-05	0.00033	CcSEcCtD
Trametinib—Anaemia—Methotrexate—psoriasis	9.27e-05	0.000329	CcSEcCtD
Trametinib—Gastrointestinal pain—Dexamethasone—psoriasis	9.2e-05	0.000327	CcSEcCtD
Trametinib—Gastrointestinal pain—Betamethasone—psoriasis	9.2e-05	0.000327	CcSEcCtD
Trametinib—Vomiting—Mycophenolate mofetil—psoriasis	9.19e-05	0.000326	CcSEcCtD
Trametinib—MAP2K1—Focal Adhesion—JUN—psoriasis	9.18e-05	0.000472	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.14e-05	0.00047	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—IL6—psoriasis	9.13e-05	0.00047	CbGpPWpGaD
Trametinib—Rash—Mycophenolate mofetil—psoriasis	9.11e-05	0.000324	CcSEcCtD
Trametinib—Dermatitis—Mycophenolate mofetil—psoriasis	9.1e-05	0.000323	CcSEcCtD
Trametinib—MAP2K1—Downstream signal transduction—STAT3—psoriasis	9.07e-05	0.000467	CbGpPWpGaD
Trametinib—Headache—Mycophenolate mofetil—psoriasis	9.05e-05	0.000322	CcSEcCtD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—STAT3—psoriasis	9.02e-05	0.000464	CbGpPWpGaD
Trametinib—Diarrhoea—Hydrocortisone—psoriasis	9.01e-05	0.00032	CcSEcCtD
Trametinib—MAP2K2—Activated TLR4 signalling—IL6—psoriasis	8.99e-05	0.000462	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—STAT3—psoriasis	8.99e-05	0.000462	CbGpPWpGaD
Trametinib—Leukopenia—Methotrexate—psoriasis	8.98e-05	0.000319	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—psoriasis	8.92e-05	0.000317	CcSEcCtD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IL6—psoriasis	8.92e-05	0.000459	CbGpPWpGaD
Trametinib—Dizziness—Prednisolone—psoriasis	8.91e-05	0.000317	CcSEcCtD
Trametinib—Asthenia—Triamcinolone—psoriasis	8.89e-05	0.000316	CcSEcCtD
Trametinib—Body temperature increased—Dexamethasone—psoriasis	8.89e-05	0.000316	CcSEcCtD
Trametinib—Abdominal pain—Betamethasone—psoriasis	8.89e-05	0.000316	CcSEcCtD
Trametinib—Body temperature increased—Betamethasone—psoriasis	8.89e-05	0.000316	CcSEcCtD
Trametinib—Abdominal pain—Dexamethasone—psoriasis	8.89e-05	0.000316	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—TYK2—psoriasis	8.89e-05	0.000457	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—IL6—psoriasis	8.86e-05	0.000456	CbGpPWpGaD
Trametinib—Insomnia—Prednisone—psoriasis	8.86e-05	0.000315	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—SOCS1—psoriasis	8.85e-05	0.000455	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	8.83e-05	0.000454	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.8e-05	0.000453	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Insulin receptor—IL6—psoriasis	8.8e-05	0.000453	CbGpPWpGaD
Trametinib—Nausea—Cyclosporine—psoriasis	8.8e-05	0.000313	CcSEcCtD
Trametinib—MAP2K2—Signaling by PDGF—STAT3—psoriasis	8.79e-05	0.000452	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—IL6—psoriasis	8.78e-05	0.000452	CbGpPWpGaD
Trametinib—Pruritus—Triamcinolone—psoriasis	8.77e-05	0.000312	CcSEcCtD
Trametinib—Cough—Methotrexate—psoriasis	8.75e-05	0.000311	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—TYK2—psoriasis	8.74e-05	0.00045	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—IL6—psoriasis	8.72e-05	0.000449	CbGpPWpGaD
Trametinib—Dizziness—Hydrocortisone—psoriasis	8.71e-05	0.000309	CcSEcCtD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—psoriasis	8.67e-05	0.000446	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ITGAL—psoriasis	8.64e-05	0.000445	CbGpPWpGaD
Trametinib—Nausea—Mycophenolate mofetil—psoriasis	8.58e-05	0.000305	CcSEcCtD
Trametinib—MAP2K2—Focal Adhesion—VEGFA—psoriasis	8.57e-05	0.000441	CbGpPWpGaD
Trametinib—Myalgia—Methotrexate—psoriasis	8.54e-05	0.000303	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—psoriasis	8.54e-05	0.000303	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—psoriasis	8.51e-05	0.000303	CcSEcCtD
Trametinib—Rash—Prednisolone—psoriasis	8.5e-05	0.000302	CcSEcCtD
Trametinib—Dermatitis—Prednisolone—psoriasis	8.49e-05	0.000302	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.48e-05	0.000301	CcSEcCtD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	8.45e-05	0.000435	CbGpPWpGaD
Trametinib—Fatigue—Prednisone—psoriasis	8.44e-05	0.0003	CcSEcCtD
Trametinib—Headache—Prednisolone—psoriasis	8.44e-05	0.0003	CcSEcCtD
Trametinib—MAP2K1—Activated TLR4 signalling—IL6—psoriasis	8.41e-05	0.000433	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—STAT3—psoriasis	8.41e-05	0.000432	CbGpPWpGaD
Trametinib—Constipation—Prednisone—psoriasis	8.38e-05	0.000298	CcSEcCtD
Trametinib—Vomiting—Hydrocortisone—psoriasis	8.37e-05	0.000297	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IFNG—psoriasis	8.33e-05	0.000428	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—TYK2—psoriasis	8.32e-05	0.000428	CbGpPWpGaD
Trametinib—Rash—Hydrocortisone—psoriasis	8.3e-05	0.000295	CcSEcCtD
Trametinib—Dermatitis—Hydrocortisone—psoriasis	8.29e-05	0.000295	CcSEcCtD
Trametinib—MAP2K1—Signaling by VEGF—IL6—psoriasis	8.29e-05	0.000427	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—SOCS1—psoriasis	8.28e-05	0.000426	CbGpPWpGaD
Trametinib—Headache—Hydrocortisone—psoriasis	8.25e-05	0.000293	CcSEcCtD
Trametinib—MAP2K1—Signaling by Insulin receptor—IL6—psoriasis	8.23e-05	0.000424	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—STAT3—psoriasis	8.22e-05	0.000423	CbGpPWpGaD
Trametinib—Dizziness—Triamcinolone—psoriasis	8.2e-05	0.000291	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—TYK2—psoriasis	8.18e-05	0.000421	CbGpPWpGaD
Trametinib—Infection—Methotrexate—psoriasis	8.13e-05	0.000289	CcSEcCtD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—psoriasis	8.11e-05	0.000417	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TNF—psoriasis	8.11e-05	0.000417	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ITGAL—psoriasis	8.08e-05	0.000416	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—REL—psoriasis	8.08e-05	0.000416	CbGpPWpGaD
Trametinib—Asthenia—Dexamethasone—psoriasis	8.07e-05	0.000287	CcSEcCtD
Trametinib—Asthenia—Betamethasone—psoriasis	8.07e-05	0.000287	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—psoriasis	8.03e-05	0.000285	CcSEcCtD
Trametinib—MAP2K1—Focal Adhesion—VEGFA—psoriasis	8.02e-05	0.000413	CbGpPWpGaD
Trametinib—Thrombocytopenia—Methotrexate—psoriasis	8.02e-05	0.000285	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—psoriasis	8.01e-05	0.000285	CcSEcCtD
Trametinib—Nausea—Prednisolone—psoriasis	8.01e-05	0.000285	CcSEcCtD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.99e-05	0.000411	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	7.96e-05	0.000409	CbGpPWpGaD
Trametinib—Pruritus—Betamethasone—psoriasis	7.96e-05	0.000283	CcSEcCtD
Trametinib—Pruritus—Dexamethasone—psoriasis	7.96e-05	0.000283	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—psoriasis	7.95e-05	0.000283	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—psoriasis	7.91e-05	0.000281	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—TYK2—psoriasis	7.91e-05	0.000407	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	7.91e-05	0.000407	CbGpPWpGaD
Trametinib—Vomiting—Triamcinolone—psoriasis	7.88e-05	0.00028	CcSEcCtD
Trametinib—MAP2K2—Immune System—IFIH1—psoriasis	7.85e-05	0.000404	CbGpPWpGaD
Trametinib—Nausea—Hydrocortisone—psoriasis	7.82e-05	0.000278	CcSEcCtD
Trametinib—Rash—Triamcinolone—psoriasis	7.82e-05	0.000278	CcSEcCtD
Trametinib—Dermatitis—Triamcinolone—psoriasis	7.81e-05	0.000277	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IFNG—psoriasis	7.79e-05	0.000401	CbGpPWpGaD
Trametinib—Headache—Triamcinolone—psoriasis	7.77e-05	0.000276	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—psoriasis	7.74e-05	0.000275	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—psoriasis	7.74e-05	0.000275	CcSEcCtD
Trametinib—Diarrhoea—Dexamethasone—psoriasis	7.7e-05	0.000273	CcSEcCtD
Trametinib—Diarrhoea—Betamethasone—psoriasis	7.7e-05	0.000273	CcSEcCtD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	7.61e-05	0.000392	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—psoriasis	7.59e-05	0.00039	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—REL—psoriasis	7.56e-05	0.000389	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HLA-B—psoriasis	7.55e-05	0.000389	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—IL6—psoriasis	7.53e-05	0.000387	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—IL6—psoriasis	7.53e-05	0.000387	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Methotrexate—psoriasis	7.46e-05	0.000265	CcSEcCtD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	7.45e-05	0.000383	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-C—psoriasis	7.44e-05	0.000383	CbGpPWpGaD
Trametinib—Dizziness—Dexamethasone—psoriasis	7.44e-05	0.000264	CcSEcCtD
Trametinib—Dizziness—Betamethasone—psoriasis	7.44e-05	0.000264	CcSEcCtD
Trametinib—Insomnia—Methotrexate—psoriasis	7.4e-05	0.000263	CcSEcCtD
Trametinib—MAP2K1—Axon guidance—TYK2—psoriasis	7.4e-05	0.000381	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—LEP—psoriasis	7.4e-05	0.000381	CbGpPWpGaD
Trametinib—Nausea—Triamcinolone—psoriasis	7.36e-05	0.000262	CcSEcCtD
Trametinib—MAP2K2—Immune System—TNFAIP3—psoriasis	7.35e-05	0.000378	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFIH1—psoriasis	7.34e-05	0.000378	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—IL6—psoriasis	7.2e-05	0.000371	CbGpPWpGaD
Trametinib—Vomiting—Dexamethasone—psoriasis	7.15e-05	0.000254	CcSEcCtD
Trametinib—Vomiting—Betamethasone—psoriasis	7.15e-05	0.000254	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—psoriasis	7.15e-05	0.000368	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	7.12e-05	0.000367	CbGpPWpGaD
Trametinib—Decreased appetite—Methotrexate—psoriasis	7.12e-05	0.000253	CcSEcCtD
Trametinib—Rash—Betamethasone—psoriasis	7.09e-05	0.000252	CcSEcCtD
Trametinib—Rash—Dexamethasone—psoriasis	7.09e-05	0.000252	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—IL6—psoriasis	7.09e-05	0.000365	CbGpPWpGaD
Trametinib—Dermatitis—Dexamethasone—psoriasis	7.09e-05	0.000252	CcSEcCtD
Trametinib—Dermatitis—Betamethasone—psoriasis	7.09e-05	0.000252	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—psoriasis	7.07e-05	0.000251	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—HLA-B—psoriasis	7.07e-05	0.000364	CbGpPWpGaD
Trametinib—Fatigue—Methotrexate—psoriasis	7.06e-05	0.000251	CcSEcCtD
Trametinib—Headache—Betamethasone—psoriasis	7.05e-05	0.00025	CcSEcCtD
Trametinib—Headache—Dexamethasone—psoriasis	7.05e-05	0.00025	CcSEcCtD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—IL6—psoriasis	7.04e-05	0.000362	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—IL6—psoriasis	7.04e-05	0.000362	CbGpPWpGaD
Trametinib—Asthenia—Prednisone—psoriasis	7.03e-05	0.00025	CcSEcCtD
Trametinib—CYP2C8—Metabolism—NDUFA5—psoriasis	6.98e-05	0.000359	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-C—psoriasis	6.96e-05	0.000358	CbGpPWpGaD
Trametinib—Pruritus—Prednisone—psoriasis	6.93e-05	0.000246	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—NFKB1—psoriasis	6.93e-05	0.000356	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—LEP—psoriasis	6.92e-05	0.000356	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TNFAIP3—psoriasis	6.87e-05	0.000354	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.85e-05	0.000352	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—NFKB1—psoriasis	6.81e-05	0.00035	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—IL6—psoriasis	6.77e-05	0.000348	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—IL6—psoriasis	6.74e-05	0.000347	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—IL6—psoriasis	6.74e-05	0.000347	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—IL6—psoriasis	6.7e-05	0.000345	CbGpPWpGaD
Trametinib—Diarrhoea—Prednisone—psoriasis	6.7e-05	0.000238	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—psoriasis	6.69e-05	0.000238	CcSEcCtD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—psoriasis	6.69e-05	0.000344	CbGpPWpGaD
Trametinib—Nausea—Dexamethasone—psoriasis	6.68e-05	0.000237	CcSEcCtD
Trametinib—Nausea—Betamethasone—psoriasis	6.68e-05	0.000237	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—CRP—psoriasis	6.68e-05	0.000343	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—IL6—psoriasis	6.67e-05	0.000343	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—IL6—psoriasis	6.63e-05	0.000341	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.51e-05	0.000335	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NFKB1—psoriasis	6.48e-05	0.000333	CbGpPWpGaD
Trametinib—Dizziness—Prednisone—psoriasis	6.48e-05	0.00023	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—psoriasis	6.47e-05	0.00023	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—psoriasis	6.47e-05	0.00023	CcSEcCtD
Trametinib—MAP2K2—Developmental Biology—PPARG—psoriasis	6.44e-05	0.000331	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NFKB1—psoriasis	6.37e-05	0.000328	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—psoriasis	6.33e-05	0.000326	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—psoriasis	6.3e-05	0.000324	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—psoriasis	6.28e-05	0.000323	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	6.28e-05	0.000323	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—psoriasis	6.28e-05	0.000323	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—psoriasis	6.27e-05	0.000323	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CRP—psoriasis	6.25e-05	0.000321	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—psoriasis	6.24e-05	0.000321	CbGpPWpGaD
Trametinib—Vomiting—Prednisone—psoriasis	6.23e-05	0.000221	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—STAT3—psoriasis	6.23e-05	0.00032	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—psoriasis	6.22e-05	0.00032	CbGpPWpGaD
Trametinib—Rash—Prednisone—psoriasis	6.18e-05	0.000219	CcSEcCtD
Trametinib—MAP2K2—Immune System—HLA-E—psoriasis	6.17e-05	0.000318	CbGpPWpGaD
Trametinib—Dermatitis—Prednisone—psoriasis	6.17e-05	0.000219	CcSEcCtD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—psoriasis	6.16e-05	0.000317	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—psoriasis	6.14e-05	0.000316	CbGpPWpGaD
Trametinib—Headache—Prednisone—psoriasis	6.14e-05	0.000218	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—STAT3—psoriasis	6.12e-05	0.000315	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NFKBIA—psoriasis	6.09e-05	0.000313	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL20—psoriasis	6.05e-05	0.000311	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.04e-05	0.000311	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PPARG—psoriasis	6.03e-05	0.00031	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP2S1—psoriasis	5.93e-05	0.000305	CbGpPWpGaD
Trametinib—Asthenia—Methotrexate—psoriasis	5.87e-05	0.000209	CcSEcCtD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	5.87e-05	0.000302	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—psoriasis	5.87e-05	0.000302	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—psoriasis	5.87e-05	0.000302	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—STAT3—psoriasis	5.82e-05	0.0003	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—psoriasis	5.82e-05	0.000299	CbGpPWpGaD
Trametinib—Nausea—Prednisone—psoriasis	5.82e-05	0.000207	CcSEcCtD
Trametinib—Pruritus—Methotrexate—psoriasis	5.79e-05	0.000206	CcSEcCtD
Trametinib—MAP2K1—Immune System—HLA-E—psoriasis	5.78e-05	0.000297	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—psoriasis	5.77e-05	0.000297	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—psoriasis	5.74e-05	0.000295	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—STAT3—psoriasis	5.73e-05	0.000295	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NFKBIA—psoriasis	5.7e-05	0.000293	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL20—psoriasis	5.66e-05	0.000291	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TYK2—psoriasis	5.65e-05	0.00029	CbGpPWpGaD
Trametinib—Diarrhoea—Methotrexate—psoriasis	5.6e-05	0.000199	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—VEGFA—psoriasis	5.59e-05	0.000288	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	5.56e-05	0.000286	CbGpPWpGaD
Trametinib—Dizziness—Methotrexate—psoriasis	5.41e-05	0.000192	CcSEcCtD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.37e-05	0.000276	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TYK2—psoriasis	5.28e-05	0.000272	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—psoriasis	5.23e-05	0.000269	CbGpPWpGaD
Trametinib—Vomiting—Methotrexate—psoriasis	5.2e-05	0.000185	CcSEcCtD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	5.2e-05	0.000268	CbGpPWpGaD
Trametinib—Rash—Methotrexate—psoriasis	5.16e-05	0.000183	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—psoriasis	5.16e-05	0.000183	CcSEcCtD
Trametinib—MAP2K2—Immune System—SOCS1—psoriasis	5.16e-05	0.000265	CbGpPWpGaD
Trametinib—Headache—Methotrexate—psoriasis	5.13e-05	0.000182	CcSEcCtD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.03e-05	0.000259	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—TYK2—psoriasis	4.99e-05	0.000257	CbGpPWpGaD
Trametinib—Nausea—Methotrexate—psoriasis	4.86e-05	0.000173	CcSEcCtD
Trametinib—MAP2K1—Immune System—SOCS1—psoriasis	4.82e-05	0.000248	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—TYK2—psoriasis	4.66e-05	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD8A—psoriasis	4.57e-05	0.000235	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CD4—psoriasis	4.51e-05	0.000232	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NFKB1—psoriasis	4.4e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-B—psoriasis	4.4e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—psoriasis	4.35e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—psoriasis	4.28e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—psoriasis	4.28e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD4—psoriasis	4.22e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NFKB1—psoriasis	4.12e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-B—psoriasis	4.12e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-A—psoriasis	4.08e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—psoriasis	4.07e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—JUN—psoriasis	4.04e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—psoriasis	4e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—psoriasis	3.99e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—STAT3—psoriasis	3.95e-05	0.000203	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CRP—psoriasis	3.89e-05	0.0002	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NFKB1—psoriasis	3.88e-05	0.0002	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—psoriasis	3.87e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-A—psoriasis	3.81e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—JUN—psoriasis	3.78e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HLA-A—psoriasis	3.76e-05	0.000194	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NDUFA5—psoriasis	3.75e-05	0.000193	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—psoriasis	3.74e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DRB1—psoriasis	3.72e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—STAT3—psoriasis	3.7e-05	0.00019	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CRP—psoriasis	3.64e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NFKB1—psoriasis	3.63e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—psoriasis	3.62e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ICAM1—psoriasis	3.57e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NFKBIA—psoriasis	3.55e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HLA-A—psoriasis	3.52e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOE—psoriasis	3.51e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DRB1—psoriasis	3.48e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—psoriasis	3.42e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ICAM1—psoriasis	3.34e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SOCS1—psoriasis	3.33e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NFKBIA—psoriasis	3.32e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APOE—psoriasis	3.29e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS2—psoriasis	3.27e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—psoriasis	3.2e-05	0.000165	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2S1—psoriasis	3.19e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—TYK2—psoriasis	3.18e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SOCS1—psoriasis	3.12e-05	0.00016	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.11e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS2—psoriasis	3.06e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—TYK2—psoriasis	2.97e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TYK2—psoriasis	2.9e-05	0.000149	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CARM1—psoriasis	2.9e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—psoriasis	2.77e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—psoriasis	2.76e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNG—psoriasis	2.72e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TYK2—psoriasis	2.72e-05	0.00014	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.71e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TYK2—psoriasis	2.68e-05	0.000138	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD4—psoriasis	2.63e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—psoriasis	2.59e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—psoriasis	2.58e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNG—psoriasis	2.54e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TYK2—psoriasis	2.51e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—LEP—psoriasis	2.46e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOE—psoriasis	2.46e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—psoriasis	2.46e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—psoriasis	2.44e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—psoriasis	2.42e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—psoriasis	2.35e-05	0.000121	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LEP—psoriasis	2.3e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOE—psoriasis	2.3e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFKBIA—psoriasis	2.29e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—psoriasis	2.28e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—psoriasis	2.27e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NFKB1—psoriasis	2.26e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—psoriasis	2.2e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKBIA—psoriasis	2.14e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NFKB1—psoriasis	2.12e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—psoriasis	2.03e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—psoriasis	1.9e-05	9.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TYK2—psoriasis	1.88e-05	9.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—psoriasis	1.88e-05	9.66e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAT—psoriasis	1.78e-05	9.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TYK2—psoriasis	1.76e-05	9.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—psoriasis	1.76e-05	9.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—psoriasis	1.63e-05	8.41e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CARM1—psoriasis	1.56e-05	8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—psoriasis	1.55e-05	8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—psoriasis	1.53e-05	7.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—psoriasis	1.52e-05	7.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFKB1—psoriasis	1.46e-05	7.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—psoriasis	1.45e-05	7.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—psoriasis	1.42e-05	7.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—psoriasis	1.42e-05	7.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOE—psoriasis	1.39e-05	7.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKB1—psoriasis	1.37e-05	7.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—psoriasis	1.33e-05	6.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—psoriasis	1.33e-05	6.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—psoriasis	1.31e-05	6.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—psoriasis	1.31e-05	6.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—psoriasis	1.24e-05	6.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—psoriasis	1.23e-05	6.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—psoriasis	1.23e-05	6.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—psoriasis	1.21e-05	6.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—psoriasis	1e-05	5.16e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAT—psoriasis	9.57e-06	4.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—psoriasis	9.39e-06	4.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—psoriasis	9.18e-06	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—psoriasis	8.59e-06	4.42e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOE—psoriasis	7.43e-06	3.82e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—psoriasis	6.48e-06	3.33e-05	CbGpPWpGaD
